Beta Bionics, Inc. (BBNX) EBITDA Margin (2024 - 2026)

Beta Bionics (BBNX) has 3 years of EBITDA Margin data on file, last reported at 81.06% in Q1 2026.

• Quarterly EBITDA Margin rose 8040.0% year-over-year to 81.06% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 60.57% (up 4071.0% YoY) and the FY2025 annual result came in at 72.68%, up 1151.0% from the prior year.
• EBITDA Margin retreated to 81.06% in Q1 2026 per BBNX's latest filing, from 41.77% in the prior quarter.
• The five-year high for EBITDA Margin was 41.77% in Q4 2025, with the low at 161.47% in Q1 2025.
• Average EBITDA Margin over 3 years is 83.18%, with a median of 81.06% recorded in 2026.
• Year-over-year, EBITDA Margin tumbled 6419 bps in 2025 and jumped 8040 bps in 2026.
• Beta Bionics' EBITDA Margin stood at 88.56% in 2024, then jumped by 53 bps to 41.77% in 2025, then plunged by 94 bps to 81.06% in 2026.
• Business Quant data shows BBNX's EBITDA Margin at 81.06% in Q1 2026, 41.77% in Q4 2025, and 51.39% in Q3 2025.